- Home
- LYEL vs TLSA Comparison
LYEL vs TLSA Comparison
Compare LYEL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- TLSA
- Stock Information
- Founded
- LYEL 2018
- TLSA 2013
- Country
- LYEL United States
- TLSA United Kingdom
- Employees
- LYEL N/A
- TLSA N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- TLSA Health Care
- Exchange
- LYEL Nasdaq
- TLSA Nasdaq
- Market Cap
- LYEL 207.7M
- TLSA 187.0M
- IPO Year
- LYEL 2021
- TLSA 2000
- Fundamental
- Price
- LYEL $12.82
- TLSA $1.69
- Analyst Decision
- LYEL Sell
- TLSA
- Analyst Count
- LYEL 2
- TLSA 0
- Target Price
- LYEL $15.00
- TLSA N/A
- AVG Volume (30 Days)
- LYEL 25.5K
- TLSA 333.7K
- Earning Date
- LYEL 11-06-2025
- TLSA 05-06-2025
- Dividend Yield
- LYEL N/A
- TLSA N/A
- EPS Growth
- LYEL N/A
- TLSA N/A
- EPS
- LYEL N/A
- TLSA N/A
- Revenue
- LYEL $60,000.00
- TLSA N/A
- Revenue This Year
- LYEL N/A
- TLSA N/A
- Revenue Next Year
- LYEL N/A
- TLSA N/A
- P/E Ratio
- LYEL N/A
- TLSA N/A
- Revenue Growth
- LYEL 11.11
- TLSA N/A
- 52 Week Low
- LYEL $7.65
- TLSA $0.63
- 52 Week High
- LYEL $32.00
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- LYEL 64.71
- TLSA 44.18
- Support Level
- LYEL $12.59
- TLSA $1.51
- Resistance Level
- LYEL $13.50
- TLSA $1.88
- Average True Range (ATR)
- LYEL 0.67
- TLSA 0.16
- MACD
- LYEL 0.18
- TLSA -0.01
- Stochastic Oscillator
- LYEL 76.87
- TLSA 29.03
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.